CNTB_OUT_1 [2025-04-01 10:53:40 -0400] 2033 Bytes | 548 tokens | Cum: 548 tkns (6.85% of 8k)
==========================================================================

Alright, let’s light it up, because it's 10:53:39 AM on Tue Apr 01, 2025 -0400, and I'm charging into Connect Biopharma (CNTB), popping from 0.55 to 0.72. Is this our star stock of the day, or just a quick blip on the radar? I've got the scoop—time to analyze!

Here's the first list of news for Connect Biopharma:

C1 - Today 09:00AM - Connect Biopharma Announces Positive Type C Meeting with the FDA for Rademikibart
C2 - Mar-31-25 04:05PM - Connect Biopharma Announces Publication of Positive Data from Global Phase 2 Trial of Rademikibart in Patients with Moderate-to-Severe Uncontrolled Asthma
C3 - Mar-31-25 04:05PM 09:00AM - Connect Biopharma Reports 2024 Full-Year Financial Results and Provides Business Update
C4 - Mar-28-25 04:05PM - Connect Biopharma Announces Receipt of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement
C5 - Mar-03-25 08:00AM - Connect Biopharma to Present at Two Upcoming Investor Conferences
C6 - Oct-15-24 07:30AM - Attovia Therapeutics Appoints Chief Financial Officer
C7 - Sep-10-24 08:00AM - Connect Biopharma to Participate in the Cantor Fitzgerald Global Healthcare Conference 2024
C8 - Sep-05-24 04:05PM - Connect Biopharma Reports First Half 2024 Financial Results and Provides Business Update

ONLY 3 RULES for AI:
==============
1) I am a document retrieval system. You are the analyst-investigator.
2) You can request items from my lists to get more info on Connect Biopharma (CNTB)
3) AFTER requesting and reading News and SEC filings you'll write a summary, set a score, high price target and headline.
Now, your response should be only 2 or 3 chars. You can say ex., C1, C2, etc., or NEX
The NEX command delivers the NEXt list of News/SEC/Metrics
There are several more lists that use our unified document retrieval system in subsequent prompts.
Your predictons will be compared to reality to rate your accuracy. Try to predict accurately. GOOD LUCK!
Please request a document, read, summarize and score. Say something like "C1".

CNTB_OUT_3 [2025-04-01 10:53:45 -0400] 1103 Bytes | 312 tokens | Cum: 862 tkns (10.78% of 8k)
==========================================================================

Showing C1 (chunk 1 of 12): C1:
**Connect Biopharma Announces Positive Type C Meeting with the FDA for Rademikibart**
Date: Today 09:00AM
Source: (GlobeNewswire)
URL: https://www.globenewswire.com/news-release/2025/04/01/3053420/0/en/Connect-Biopharma-Announces-Positive-Type-C-Meeting-with-the-FDA-for-Rademikibart.html

April 01, 2025 09:00 ET| Source:Connect Biopharma Holdings LimitedConnect Biopharma Holdings Limited

– FDA aligned on plan to initiate parallel Phase 2 trials of rademikibart in patients with moderate-to-severe asthma or COPD experiencing an acute exacerbation –

SAN DIEGO, April 01, 2025 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect or Connect Biopharma), a clinical-stage biopharmaceutical company focused on transforming acute and chronic care of asthma and chronic obstructive pulmonary disease (COPD), today announced positive feedback from its Type C meeting wit

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

CNTB_OUT_5 [2025-04-01 10:53:46 -0400] 989 Bytes | 289 tokens | Cum: 1248 tkns (15.60% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-04-01T13:23:22Z - Connect Biopharma Announces Positive Type C Meeting with the FDA for Rademikibart...
A2 - 2025-04-01T13:11:05Z - Connect Biopharma Announces Positive Type C Meeting with the FDA for Rademikibart...
A3 - 2025-04-01T13:05:37Z - Connect Biopharma (CNTB) Announces Positive Type C Meeting with the FDA for Rademikibart...
A4 - 2025-03-31T20:14:06Z - Connect Biopharma Announces Publication of Positive Data from Global Phase 2 Trial of Rademikibart i...
A5 - 2025-03-31T20:20:44Z - Connect Biopharma (CNTB) Announces Publication of Positive Data from Global Phase 2 Trial of Rademik...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

CNTB_OUT_7 [2025-04-01 10:53:50 -0400] 1099 Bytes | 315 tokens | Cum: 1565 tkns (19.56% of 8k)
==========================================================================

Showing A1 (chunk 1 of 12): A1:
**Connect Biopharma Announces Positive Type C Meeting with the FDA for Rademikibart**Date: 2025-04-01Source: {'uri': 'manilatimes.net', 'dataType': 'news', 'title': 'The Manila times'}URL: https://www.manilatimes.net/2025/04/01/tmt-newswire/globenewswire/connect-biopharma-announces-positive-type-c-meeting-with-the-fda-for-rademikibart/2084400Gentex Announces Closing of VOXX International Acquisition

- FDA aligned on plan to initiate parallel Phase 2 trials of rademikibart in patients with moderate-to-severe asthma or COPD experiencing an acute exacerbation -

- Expect to initiate both trials in Q2 2025 -

SAN DIEGO, April 01, 2025 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect or Connect Biopharma), a clinical-stage biopharmaceutical company focused on transforming acute and chronic care of asthma and chronic obstructive pulmonary disease (COPD), toda

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

CNTB_OUT_9 [2025-04-01 10:53:51 -0400] 1231 Bytes | 353 tokens | Cum: 2005 tkns (25.06% of 8k)
==========================================================================

This is our final list of news.
News AI can literally read just by asking.
Don't miss the breaking news!

B1 - 2024-07-01T12:00:00Z - Connect Biopharma to Participate in the Leerink Partners I&I and Metabolism Therapeutics Forum
B2 - 2024-06-12T22:03:00Z - Connect Biopharma Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
B3 - 2024-06-12T20:15:00Z - Connect Biopharma Announces New Leadership and Chair of the Board of Directors
B4 - 2024-05-22T20:05:00Z - Connect Biopharma Presents Late-Breaking Abstract at the American Thoracic Society 2024 International Conference on the Positive Rademikibart Data from its Global Phase 2b in Patients with Moderate-to-Severe Asthma
B5 - 2024-05-07T10:30:00Z - Connect Biopharma to Present a Late-Breaking Abstract at the American Thoracic Society (ATS) 2024 International Conference on the Positive Results from the Global Phase 2b Trial of Rademikibart in Patients with Moderate-to-Severe Asthma
B6 - 2024-04-16T20:05:00Z - Connect Biopharma Reports Full Year 2023 Financial Results and Provides Business Update

Request an article by its reference number. (Ex., "B1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

CNTB_OUT_11 [2025-04-01 10:53:55 -0400] 1098 Bytes | 294 tokens | Cum: 2301 tkns (28.76% of 8k)
==========================================================================

Showing B1 (chunk 1 of 2): B1:
**Connect Biopharma to Participate in the Leerink Partners I&I and Metabolism Therapeutics Forum**Date: Unknown DateSource: Unknown SourceURL: https://www.globenewswire.com/news-release/2024/07/01/2906639/0/en/Connect-Biopharma-to-Participate-in-the-Leerink-Partners-I-I-and-Metabolism-Therapeutics-Forum.htmlSAN DIEGO, CA and TIACANG, China, July 01, 2024 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect or the Company), a U.S.-headquartered, global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases through the development of therapies derived from T cell-driven research, announced today that Barry Quart, Chief Executive Officer, David Szekeres, President and Steven Chan, Chief Financial officer will be hosting one-on-one investor meetings at the Leerink Partners Inflammation and Immun

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

CNTB_OUT_13 [2025-04-01 10:53:56 -0400] 1099 Bytes | 282 tokens | Cum: 2678 tkns (33.48% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

S1 - 2025-04-01 8-K Item 7.01 Regulation FD Disclosure.

On April 1, 2025, Connect Biopharma Holdings Limited (the Company) issued a press release announcing positive feedback from its Type C meeting with the U.S. Food and Drug Administration (FDA), Division of Pulmonology, Allergy, and Critical Ca...

S2 - 2025-03-31 10-K ITEM 7. MGT DISC & ANALYSIS OF FIN COND & RESULTS OF OPER.

The following discussion and analysis of our financial condition and results of operations should be read together with our audited financial statements and the related notes and othe...

S3 - 2025-03-31 8-K Item 2.02 Results of Oper and Fin Cond.

On March 31, 2025, Connect Biopharma Holdings Limited (the Company) issued a press release announcing its financial results for the fiscal year ended December 31, 2024. A copy of the press release is attached hereto as Ex...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

CNTB_OUT_15 [2025-04-01 10:54:02 -0400] 1098 Bytes | 278 tokens | Cum: 2958 tkns (36.98% of 8k)
==========================================================================

Showing S1 (chunk 1 of 2): S1:
Item 7.01 Regulation FD Disclosure.

On April 1, 2025, Connect Biopharma Holdings Limited (the Company) issued a press release announcing positive feedback from its Type C meeting with the U.S. Food and Drug Administration (FDA), Division of Pulmonology, Allergy, and Critical Care, in the Office of Immunology and Inflammation (the Type C Meeting). A copy of the press release is filed herewith as Exhibit 99.1 and is incorporated herein by reference. The information in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, is intended to be furnished and shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

CNTB_OUT_17 [2025-04-01 10:54:18 -0400] 3283 Bytes | 818 tokens | Cum: 3930 tkns (49.12% of 8k)
==========================================================================

This is our set of metrics.
Please analyze the numbers.

+--------------------+-----------------------+-------------------------+-----------------------+
| Volume: 275,991 | Perf Month: -17.90% | Option/Short: Yes / Yes | Sales Y/Y TTM: - |
+--------------------+-----------------------+-------------------------+-----------------------+
| Avg Volume: 21.16K | Perf Quarter: -37.15% | Short Float: 0.02% | ROE: - |
+--------------------+-----------------------+-------------------------+-----------------------+
| Rel Volume: 60.48 | Index: - | Short Ratio: 0.48 | ROI: - |
+--------------------+-----------------------+-------------------------+-----------------------+
| RSI (14): 42.65 | Market Cap: 39.58M | Short Interest: 0.01M | Sales Surprise: - |
+--------------------+-----------------------+-------------------------+-----------------------+
| ATR (14): 0.09 | Shs Outstand: 55.25M | Beta: -0.22 | EPS Surprise: -12.26% |
+--------------------+-----------------------+-------------------------+-----------------------+
| SMA20: -9.45% | Shs Float: 53.25M | Sales Q/Q: - | P/E: - |
+--------------------+-----------------------+-------------------------+-----------------------+
| SMA50: -18.88% | Inst Own: 5.76% | Sales past 5Y: 0.00% | Earnings: Mar 31 BMO |
+--------------------+-----------------------+-------------------------+-----------------------+
| SMA200: -36.06% | Insider Own: - | Employees: - | |
+--------------------+-----------------------+-------------------------+-----------------------+
| Perf Week: -11.55% | Insider Trans: - | Debt/Eq: 0.00 | |
+--------------------+-----------------------+-------------------------+-----------------------+

The next section covers any insider trading.
If this section may be blank due to no recent filings.

[Company Financial Summary]
[Company Details]
Name: N/A
Market Cap: N/A
Shares Outstanding: N/A
Sector: N/A

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): N/A
Net Income: N/A
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 0.66
Average Volume: 39321.41
30-Day High: 0.88
30-Day Low: 0.55
No detailed financial data available.
==== END OF FINANCIAL REPORT ====

You are now requested to make a summary analysis.
Save explaining why you didn't have enough information for the final survey.

Now, complete this report with the following:

1) Brief Summary: explain your findings in succinct wording.
2) MARKET_SCORE: If you calculate a 92% likelihood of an upward moves, say: MARKET_SCORE[92]
3) PRICE_TARGET: If you think the high today will be 50% higher, add to the price.
Eg., If the current price is $5.00, add 50%. Thus, PRICE_TARGET[$7.50] -- It should be at or above the current price.
4) Provide a thought-provoking take, 6-10 words, to use for the headline of this news story.
Like this: AI_RPT_HEADLINE: [6-12 words headline for news story, distilled from summary]

1) Brief Summary, 2) MARKET_SCORE, 3) PRICE_TARGET, and 4) AI_RPT_HEADLINE

CNTB_OUT_19 [2025-04-01 10:54:20 -0400] 676 Bytes | 167 tokens | Cum: 4445 tkns (55.56% of 8k)
==========================================================================

Finally, if more data could have improved your confidence which would you have chosen? **Choose one option:**
-> X0 <- Nothing more would have helped my analysis
-> X1 <- More stock-specific news
-> X2 <- More SEC filings (10-K, 10-Q, 8-K) Financials, risk disclosures, and business changes
-> X3 <- More SEC Insider Trading (Form 3, 4, 5) Direct buys/sells from executives and institutions
-> X4 <- Broader sector & market news
-> X5 <- Your past analysis on similar companies (specify metrics)
-> X6 <- More financial metrics
-> X7 <- Your past analysis on this exact company
-> X8 <- Something altogether different (explain...)

CNTB_IN_21 [2025-04-01 10:54:20 -0400] 126 Bytes | 29 tokens | Cum: 4502 tkns (56.27% of 8k)
==========================================================================

====================================
[2025-04-01 10:54:20] # Analysis Completed
Elapsed Time: 41.50 seconds